ecq the next isn?, page-13

Well well well looky here what do we have. Washer and Macdonald on board with generous incentive packages to get this over the line.

Cynata is the play here, there has been a lot of work behind the scenes to mould this together by the looks. New directors, acquiring cynata and the listing of the cynata technology (1/4m) ecq shares.

"Cynata’s core technology revolves around the production of mesenchymoangioblasts
(MCAs). MCAs are one of the earliest forms of mesenchymal cell, which go on to produce
smooth muscle, bones, cartilage, blood vessels and other tissue types. Immediate
opportunities present themselves in the form of treatments for circulatory disorders. The
first application targeted for therapies prepared using Cynata’s proprietary MCAs is
Critical Limb Ischaemia (CLI) a complication of diabetes. CLI represents a $3bn market.
Further development will target other complications of diabetes, other indications
involving a loss of circulation or damaged blood vessels and graft-versus-host disease.
These conditions represent a combined market worth over $10bn."

Taken an entry on a 3-5 year hold. The investment case to me is compelling on a number of fronts. I would not be counting on those 80m shares coming back to market - hence my entry.

Remember this video;

http://www.youtube.com/watch?v=3Uv-AFjlqNY